[ad_1] Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage…
[ad_1] Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage…
[ad_1] In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. Rafael Henrique | SOPA Images | Lightrocket | Getty Images The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. The FDA’s decision means Madrigal…
[ad_1] Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC Weight Watchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster…
[ad_1] Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program. Starting…
[ad_1] There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of…
[ad_1] Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg |…
[ad_1] Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Cigna on Thursday said it will limit how much health plans and employers spend on weight loss drugs each year in a bid to expand insurance coverage for those highly…
[ad_1] Jonathan Raa | Nurphoto | Getty Images Novo Nordisk shares climbed 7% on Thursday, hitting a fresh record high after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug. The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed…
[ad_1] This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim in eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial…
